The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
Open accessAbstract
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December 2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up extraordinary challenges. This unprecedented situation led to the inception of numerous fundamental research protocols and many clinical trials. It quickly became apparent that although COVID-19, in the vast majority of cases, was a benign disease, it could also develop a severe form with sometimes fatal outcomes. Cytokines are central to the pathophysiology of COVID-19; while some of them are beneficial (type-I interferon, interleukin-7), others appear detrimental (interleukin-1β, -6, and TNF-α) particularly in the context of the so-called cytokine storm. Yet another characteristic of the disease has emerged: concomitant immunodeficiency, notably involving impaired type-I interferon response, and lymphopenia. This review provides an overview of current knowledge on COVID-19 immunopathology. We discuss the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as we mention the two patterns observed in severe COVID-19 (i.e. interleukin-1β-driven macrophage activation syndrome vs. interleukin-6-driven immune dysregulation). Next, reviewing current evidence drawn from clinical trials, we examine a number of cytokine and anti-cytokine therapies, including interleukin-1, -6, and TNF inhibitors, as well as less targeted therapies, such as corticosteroids, chloroquine, or JAK inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedWang, X., Xu, W., Hu, G., Xia, S., Sun, Z., Liu, Z., Xie, Y., Zhang, R., Jiang, S., & Lu, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0498-4 · Cited by 175
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884 · cited 12×
“lating IL-1β, IL1-Ra, and IL-18 [23,26] and synergistic upregulation of IL1 and IL1RN genes in the lung [34].”
InfluentialClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 4×
“rectly recognizing viral RNA is scant [31], however, NLRs are more possibly involved in detecting intracellular homeostasis perturbations or danger signals, such as ROS production [32,33].”
InfluentialGrasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 17×
“This results in an impaired clearance of apoptic cells or infected/activated macrophages, an increase in viral replication and dissemination, followed by an IL-18/IFN-γ feedforward loop activating macrophages, culminating in multiple cytokine release, hemophagocytosis, coagulopathy, and ARDS (Fig.”
InfluentialGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775 · cited 4×
“Immunohistochemical staining demonstrated decreased rates of CD4+ and CD8+ T cells in the spleen and lymph nodes [61].”
InfluentialClinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,911
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Giamarellos-Bourboulis, E. J., Netea, M. G., Rovina, N., Akinosoglou, K., Antoniadou, A., Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.-E., Katsaounou, P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.009 · Cited by 2,045 · cited 3×
“have come to the conclusion that two patterns of immune dysfunction exist in worsening COVID-19: (i) one pattern highly suggestive of macrophage activation syndrome (hyperferritinemia and elevated H score : 25% of patients), which is driven by IL-1β; and (ii) one pattern with immune dysregulation driven by IL-6 [71].”
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727 · cited 1×
“Patients with high viral loads and long virus-shedding periods are at higher risk of severe COVID-19 [15] .”
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701
RIG-I-like receptors: their regulation and roles in RNA sensing
Rehwinkel, J., & Gack, M. U. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,699
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J.-Q., Du, P., Wei, D., Zhang, Y., Sun, X.-X., Gong, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00426-x · Cited by 1,593
Adult haemophagocytic syndrome
Ramos-Casals, M., Brito-Zerón, P., López-Guillermo, A., Khamashta, M. A., & Bosch, X. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61048-x · Cited by 1,442
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 3×
“Inhibitors of IL-6 or its receptor have been successful in treating other cytokine storm syndromes, such as reHLH associated with adultonset Still’s disease [120], or CRS secondary to CAR T cell therapies [28,121].”
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217 · cited 3×
“Evidence is mainly derived from experience with SARS-CoV and MERS-CoV infections [95].”
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
Wang, F., Nie, J., Wang, H., Zhao, Q., Xiong, Y., Deng, L., Song, S., Ma, Z., Mo, P., & Zhang, Y. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa150 · Cited by 1,131
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122
Allen, I. C., Scull, M. A., Moore, C. B., Holl, E. K., McElvania-TeKippe, E., Taxman, D. J., Guthrie, E. H., Pickles, R. J., & Ting, J. P.-Y. (2009) · Immunity · doi:10.1016/j.immuni.2009.02.005 · Cited by 1,113
Fu, L., Wang, B., Yuan, T., Chen, X., Ao, Y., Fitzpatrick, T., Li, P., Zhou, Y., Lin, Y.-F., Duan, Q., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.041 · Cited by 1,103
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., Guo, D., Hu, W., Yang, J., Tang, Z., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1747363 · Cited by 1,076 · cited 3×
“Intriguingly, while being central to cytokine storm occurrence in SARS-CoV infection [148], IFN-γ was not found to be elevated in the sera or BALFs of patients with severe forms of COVID-19 [22,23,26,149].”
Lung pathology of fatal severe acute respiratory syndrome
Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., Chu, C. M., Hui, P. K., Mak, K. L., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13413-7 · Cited by 1,076
Age-dependent dysregulation of innate immunity
Shaw, A. C., Goldstein, D. R., & Montgomery, R. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3547 · Cited by 1,061
Borba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C.-C., Edwards, K. M., Gandhi, R., Muller, W. J., O’Horo, J. C., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,033
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa449 · Cited by 1,020
[A pathological report of three COVID-19 cases by minimal invasive autopsies].
Yao, X. H., Li, T. Y., He, Z. C., Ping, Y. F., Liu, H. W., Yu, S. C., Mou, H. M., Wang, L. H., Zhang, H. R., Fu, W. J., et al. (2020) · PubMed · doi:10.3760/cma.j.cn112151-20200312-00193 · Cited by 963
Zheng, H.-Y., Zhang, M., Yang, C.-X., Zhang, N., Wang, X.-C., Yang, X.-P., Dong, X.-Q., & Zheng, Y.-T. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0401-3 · Cited by 940
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Dysregulation of Immune Response in Patients with COVID-19 in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3541136 · Cited by 898
Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis
Coomes, E. A., & Haghbayan, H. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2141 · Cited by 883
Yang, Y., Shen, C., Li, J., Yuan, J., Wei, J., Huang, F., Wang, F., Li, G., Li, Y., Xing, L., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.027 · Cited by 872
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
Inflammatory caspases and inflammasomes: master switches of inflammation
Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402038 · Cited by 820
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102452 · Cited by 763
Molina, J. M., Delaugerre, C., Le Goff, J., Mela-Lima, B., Ponscarme, D., Goldwirt, L., & de Castro, N. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.03.006 · Cited by 749
An interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
Chen, J., Liu, D., Liu, L., Liu, P., Xu, Q., Xia, L., Ling, Y., Huang, D. F., Song, S., Zhang, D., et al. (2020) · PubMed · doi:10.3785/j.issn.1008-9292.2020.03.03 · Cited by 664
The Immunology of Macrophage Activation Syndrome
Crayne, C. B., Albeituni, S., Nichols, K. E., & Cron, R. Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00119 · Cited by 633
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines
Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000702 · Cited by 606
Jensen, S., & Thomsen, A. R. (2012) · Journal of Virology · doi:10.1128/jvi.05738-11 · Cited by 604
On the use of corticosteroids for 2019-nCoV pneumonia
Shang, L., Zhao, J., Hu, Y., Du, R., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30361-5 · Cited by 604
Ziegler, H. K., & Unanue, E. R. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.1.175 · Cited by 570
Mahévas, M., Tran, V.-T., Roumier, M., Chabrol, A., Paule, R., Guillaud, C., Fois, E., Lepeule, R., Szwebel, T.-A., Lescure, F.-X., et al. (2020) · BMJ · doi:10.1136/bmj.m1844 · Cited by 566
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Fantini, J., Di Scala, C., Chahinian, H., & Yahi, N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105960 · Cited by 561
Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome
Chen, I.-Y., Moriyama, M., Chang, M.-F., & Ichinohe, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00050 · Cited by 547
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Feldmann, M., Maini, R. N., Woody, J. N., Holgate, S. T., Winter, G., Rowland, M., Richards, D., & Hussell, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30858-8 · Cited by 536
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531
The Role of Interleukin 6 During Viral Infections
Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L., & Borca, M. V. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01057 · Cited by 526
Poeck, H., Bscheider, M., Gross, O., Finger, K., Roth, S., Rebsamen, M., Hannesschläger, N., Schlee, M., Rothenfusser, S., Barchet, W., et al. (2010) · Nature Immunology · doi:10.1038/ni.1824 · Cited by 521
Haga, S., Yamamoto, N., Nakai-Murakami, C., Osawa, Y., Tokunaga, K., Sata, T., Yamamoto, N., Sasazuki, T., & Ishizaka, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711241105 · Cited by 521
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
Self-citationNieto-Torres, J. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Torres, J., Aguilella, V. M., & Enjuanes, L. (2015) · Virology · doi:10.1016/j.virol.2015.08.010 · Cited by 511
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Siu, K., Yuen, K., Castano‐Rodriguez, C., Ye, Z., Yeung, M., Fung, S., Yuan, S., Chan, C., Yuen, K., Enjuanes, L., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802418r · Cited by 502
Glowacka, I., Bertram, S., Herzog, P., Pfefferle, S., Steffen, I., Muench, M. O., Simmons, G., Hofmann, H., Kuri, T., Weber, F., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01248-09 · Cited by 495
Blocking IL-1 in systemic inflammation
Dinarello, C. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050640 · Cited by 494
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Lokugamage, K. G., Hage, A., de Vries, M., Valero-Jimenez, A. M., Schindewolf, C., Dittmann, M., Rajsbaum, R., & Menachery, V. D. (2020) · Journal of Virology · doi:10.1128/jvi.01410-20 · Cited by 483
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
Sportès, C., Hakim, F. T., Memon, S. A., Zhang, H., Chua, K. S., Brown, M. R., Fleisher, T. A., Krumlauf, M. C., Babb, R. R., Chow, C. K., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071681 · Cited by 476
Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., & Lau, Y. L. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 471
Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E. G., D’Cruz, D. P., & Shoenfeld, Y. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-185 · Cited by 466
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M. (2020) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xcdary · Cited by 466
COVID-19 infection and rheumatoid arthritis: Faraway, so close
Favalli, E. G., Ingegnoli, F., De Lucia, O., Cincinelli, G., Cimaz, R., & Caporali, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102523 · Cited by 454
Gong, J., Dong, H., Xia, Q.-S., Huang, Z.-Y., Wang, D.-K., Zhao, Y., Liu, W.-H., Tu, S.-H., Zhang, M.-M., Wang, Q., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05681-5 · Cited by 435
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial
Francois, B., Jeannet, R., Daix, T., Walton, A. H., Shotwell, M. S., Unsinger, J., Monneret, G., Rimmelé, T., Blood, T., Morre, M., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98960 · Cited by 431
Interferon-α2b Treatment for COVID-19
Zhou, Q., Chen, V., Shannon, C. P., Wei, X.-S., Xiang, X., Wang, X., Wang, Z.-H., Tebbutt, S. J., Kollmann, T. R., & Fish, E. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01061 · Cited by 417
Taylor, P. C., Peters, A. M., Paleolog, E., Chapman, P. T., Elliott, M. J., McCloskey, R., Feldmann, M., & Maini, R. N. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<38::aid-anr6>3.0.co;2-l · Cited by 405
Mehta, A. K., Gracias, D. T., & Croft, M. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.003 · Cited by 404
Shi, C.-S., Nabar, N. R., Huang, N.-N., & Kehrl, J. H. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0181-7 · Cited by 404
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Weiss, E. S., Girard-Guyonvarc’h, C., Holzinger, D., de Jesus, A. A., Tariq, Z., Picarsic, J., Schiffrin, E. J., Foell, D., Grom, A. A., Ammann, S., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820852 · Cited by 395
Lau, S. K. P., Lau, C. C. Y., Chan, K.-H., Li, C. P. Y., Chen, H., Jin, D.-Y., Chan, J. F. W., Woo, P. C. Y., & Yuen, K.-Y. (2013) · Journal of General Virology · doi:10.1099/vir.0.055533-0 · Cited by 392
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
Canna, S. W., Girard, C., Malle, L., de Jesus, A., Romberg, N., Kelsen, J., Surrey, L. F., Russo, P., Sleight, A., Schiffrin, E., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.10.022 · Cited by 366
Yang, Z., Liu, J., Zhou, Y., Zhao, X., Zhao, Q., & Liu, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.062 · Cited by 363
Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.300 · Cited by 330
Paleolog, E. M., Young, S., Stark, A. C., McCloskey, R. V., Feldmann, M., & Maini, R. N. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199807)41:7<1258::aid-art17>3.0.co;2-1 · Cited by 325
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Kotch, C., Barrett, D., & Teachey, D. T. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1629904 · Cited by 324
Pugin, J., Ricou, B., Steinberg, K. P., Suter, P. M., & Martin, T. R. (1996) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.153.6.8665045 · Cited by 323 · cited 1×
“Elevated IL-1β is central to ARDS [132] and HLH [89, 133] .”
Al-Tawfiq, J. A., Momattin, H., Dib, J., & Memish, Z. A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.12.003 · Cited by 322
Caso, F., Costa, L., Ruscitti, P., Navarini, L., PUENTE, A. D., Giacomelli, R., & Scarpa, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102524 · Cited by 317
IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis
Unsinger, J., McGlynn, M., Kasten, K. R., Hoekzema, A. S., Watanabe, E., Muenzer, J. T., McDonough, J. S., Tschoep, J., Ferguson, T. A., McDunn, J. E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903151 · Cited by 312
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Kamphuis, E., Junt, T., Waibler, Z., Forster, R., & Kalinke, U. (2006) · Blood · doi:10.1182/blood-2006-06-027599 · Cited by 306
Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis
Karakike, E., & Giamarellos-Bourboulis, E. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00055 · Cited by 304
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212608 · Cited by 291
van den Borne, B. E. E. M., Dijkmans, B. A. C., de ROOY, H. H., le Cessie, S., & Verweij, C. (1997) · PubMed · Cited by 281
Fautrel, B. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.08.006 · Cited by 276
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 273
Type I IFN immunoprofiling in COVID-19 patients
Trouillet-Assant, S., Viel, S., Gaymard, A., Pons, S., Richard, J.-C., Perret, M., Villard, M., Brengel-Pesce, K., Lina, B., Mezidi, M., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.029 · Cited by 265
Self-citationJAK inhibitors for the treatment of autoimmune and inflammatory diseases
Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & Sève, P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102390 · Cited by 264
Self-citationDiagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue
Shen, K.-L., & Yang, Y.-H. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-020-00344-6 · Cited by 261
Carter, S. J., Tattersall, R. S., & Ramanan, A. V. (2019) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 259
New concepts in antimalarial use and mode of action in dermatology
Kalia, S., & Dutz, J. P. (2007) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2007.00131.x · Cited by 257
Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis
Li, H., Xiang, X., Ren, H., Xu, L., Zhao, L., Chen, X., Long, H., Wang, Q., & Wu, Q. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.035 · Cited by 255
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Arabi, Y. M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., Jose, J., Alraddadi, B., Almotairi, A., Al Khatib, K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz544 · Cited by 248
Adult-Onset Still Disease: Manifestations, Treatment, Outcome, and Prognostic Factors in 57 Patients
Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., Broussolle, C., & Sève, P. (2014) · Medicine · doi:10.1097/md.0000000000000021 · Cited by 243
Self-citationde Jesus, A. A., Hou, Y., Brooks, S., Malle, L., Biancotto, A., Huang, Y., Calvo, K. R., Marrero, B., Moir, S., Oler, A. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129301 · Cited by 239
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS‐CoV‐2 Viral Load
Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Rosa Calatrava, M., Mentré, F., et al. (2020) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12543 · Cited by 239
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
Zhou, W., Liu, Y., Tian, D., Wang, C., Wang, S., Cheng, J., Hu, M., Fang, M., & Gao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0127-9 · Cited by 234
SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death
Yue, Y., Nabar, N. R., Shi, C.-S., Kamenyeva, O., Xiao, X., Hwang, I.-Y., Wang, M., & Kehrl, J. H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0917-y · Cited by 231
Högner, K., Wolff, T., Pleschka, S., Plog, S., Gruber, A. D., Kalinke, U., Walmrath, H.-D., Bodner, J., Gattenlöhner, S., Lewe-Schlosser, P., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003188 · Cited by 227
Shoenfeld, Y. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102538 · Cited by 227
Plasmacytoid dendritic cells control T-cell response to chronic viral infection
Cervantes-Barragan, L., Lewis, K. L., Firner, S., Thiel, V., Hugues, S., Reith, W., Ludewig, B., & Reizis, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117359109 · Cited by 215
Gritti, G., Raimondi, F., Bottazzi, B., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Micò, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01299-x · Cited by 210
Perales, M.-A., Goldberg, J. D., Yuan, J., Koehne, G., Lechner, L., Papadopoulos, E. B., Young, J. W., Jakubowski, A. A., Zaidi, B., Gallardo, H., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437236 · Cited by 208
Lansbury, L. E., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Shen Lim, W. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004093 · Cited by 207 · cited 1×
“tional studies in influenza found a higher risk of mortality and secondary infections with (high-dose) corticosteroids [172].”
Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection
Yang, M. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3527420 · Cited by 200
Brisse, E., Wouters, C. H., & Matthys, P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14147 · Cited by 197
Ben‐Zvi, I., Kukuy, O., Giat, E., Pras, E., Feld, O., Kivity, S., Perski, O., Bornstein, G., Grossman, C., Harari, G., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39995 · Cited by 188
Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart
Jamilloux, Y., Gerfaud-Valentin, M., Martinon, F., Belot, A., Henry, T., & Sève, P. (2015) · Immunologic Research · doi:10.1007/s12026-014-8561-9 · Cited by 186
Self-citationInterferon-β 1a and SARS Coronavirus Replication
Hensley, L. E., Fritz, E. A., Jahrling, P. B., Karp, C., Huggins, J. W., & Geisbert, T. W. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1002.030482 · Cited by 183
Monteagudo, L. A., Boothby, A., & Gertner, E. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11135 · Cited by 183
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
Vallurupalli, M., & Berliner, N. (2019) · Blood · doi:10.1182/blood.2019002289 · Cited by 170
Type I Interferons as Regulators of Lung Inflammation
Makris, S., Paulsen, M. T., & Johansson, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00259 · Cited by 168
COVID-19 early warning score: a multi-parameter screening tool to identify highly suspected patients
Song, C.-Y., Xu, J., He, J.-Q., & Lu, Y.-Q. (2020) · medRxiv · doi:10.1101/2020.03.05.20031906 · Cited by 166
Macrophage activation syndrome and cytokine-directed therapies
Schulert, G. S., & Grom, A. A. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.03.002 · Cited by 163
Ramanan, A. V., & Schneider, R. (2003) · PubMed · Cited by 160
Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome
Bracaglia, C., Prencipe, G., & De Benedetti, F. (2017) · Pediatric Rheumatology · doi:10.1186/s12969-016-0130-4 · Cited by 160
Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P., & Sysa-Jedrzejowska, A. (2006) · Lupus · doi:10.1191/0961203306lu2299oa · Cited by 158
High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients
Lagunas‐Rangel, F. A., & Chávez‐Valencia, V. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25900 · Cited by 158
Antimalarial agents: Closing the gate on toll‐like receptors?
Lafyatis, R., York, M. R., & Marshak‐Rothstein, A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22157 · Cited by 153
Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis
Seguin, A., Galicier, L., Boutboul, D., Lemiale, V., & Azoulay, É. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.11.004 · Cited by 151
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Albeituni, S., Verbist, K., Tedrick, P., Sheppard, H., Picarsic, J. L., Bassett, R., & Nichols, K. E. (2019) · Blood · doi:10.1182/blood.2019000761 · Cited by 150
In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 144
Targeting interferons and their pathways in systemic lupus erythematosus
Chasset, F., & Arnaud, L. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.009 · Cited by 138
Corticosteroid therapy for sepsis: a clinical practice guideline
Lamontagne, F., Rochwerg, B. N., Lytvyn, L., Guyatt, G. H., Møller, M. H., Annane, D., Kho, M. E., Adhikari, N. K. J., Machado, F. R., Vandvik, P. O., et al. (2018) · BMJ · doi:10.1136/bmj.k3284 · Cited by 138
Etanercept in the treatment of macrophage activation syndrome.
Prahalad, S., Bove, K. E., Dickens, D., Lovell, D. J., & Grom, A. (2001) · PubMed · Cited by 137
Tan, Y.-X., Tan, T. H. P., Lee, M. J.-R., Tham, P.-Y., Gunalan, V., Druce, J. D., Birch, C. J., Catton, M. G., Fu, N. Y., Yu, V. C. K., et al. (2007) · Journal of Virology · doi:10.1128/jvi.00090-07 · Cited by 133
Meng, Z., Wang, T., Chen, L., Chen, X., Li, L., Qin, X., Li, H., & Luo, J. D. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666210429083050 · Cited by 129
Suppressor of Cytokine Signaling 3 Regulates Proliferation and Activation of T-helper Cells
Yu, C., Mahdi, R. M., Ebong, S., Vistica, B. P., Gery, I., & Egwuagu, C. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300489200 · Cited by 124
Emapalumab: First Global Approval
Al-Salama, Z. T. (2019) · Drugs · doi:10.1007/s40265-018-1046-8 · Cited by 113
Anakinra in children and adults with Still’s disease
Vastert, S. J., Jamilloux, Y., Quartier, P., Ohlman, S., Koskinen, L. O., Kullenberg, T., Franck‐Larsson, K., Fautrel, B., & Benedetti, F. D. (2019) · Rheumatology · doi:10.1093/rheumatology/kez350 · Cited by 113
Self-citationACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia
Rivellese, F., & Prediletto, E. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102536 · Cited by 109
Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease
Kumar, A., Liang, B., Aarthy, M., Singh, S. K., Garg, N., Mysorekar, I. U., & Giri, R. (2018) · ACS Omega · doi:10.1021/acsomega.8b01002 · Cited by 103
The expanding spectrum of hemophagocytic lymphohistiocytosis
Filipovich, A. H. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32834c22f5 · Cited by 98
Interleukin-6 blockade for severe COVID-19Preprint
Roumier, M., Paule, R., Groh, M., Vallée, A., Ackermann, F., & for the Foch COVID-19 Study Group (2020) · medRxiv · doi:10.1101/2020.04.20.20061861 · Cited by 92
Thiébaut, R., Jarné, A., Routy, J., Sereti, I., Fischl, M. A., Ive, P., Speck, R. F., D’Offizi, G., Casari, S., Commenges, D., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw065 · Cited by 89
Akpovwa, H. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3182 · Cited by 88
Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons
Scagnolari, C., Vicenzi, E., Bellomi, F., Stillitano, M. G., Pinna, D., Poli, G., Clementi, M., DIANZANI, F., & Antonelli, G. (2004) · Antiviral Therapy · doi:10.1177/135965350400900618 · Cited by 87
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Dholaria, B., Bachmeier, C. A., & Locke, F. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0324-z · Cited by 85
IL-18 Serum Level in Adult Onset Still’s Disease: A Marker of Disease Activity
Colafrancesco, S., Priori, R., Alessandri, C., Perricone, C., Pendolino, M., Picarelli, G., & Valesini, G. (2012) · International Journal of Inflammation · doi:10.1155/2012/156890 · Cited by 81
Löffler, B., Bohn, E., Hesse, B., & Kunze, H. (1985) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(85)90114-6 · Cited by 78
Jiang, Y., Li, J., Teng, Y., Sun, H. C., Tian, G., He, L., Li, P., Chen, Y., Guo, Y., Li, J., et al. (2019) · Viruses · doi:10.3390/v11010039 · Cited by 78
Assil, S., Coléon, S., Dong, C., Décembre, É., Sherry, L., Allatif, O., Webster, B., & Dreux, M. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.03.005 · Cited by 74
The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus
McDermott, J., Mitchell, H. D., Gralinski, L. E., Eisfeld, A. J., Josset, L., Bankhead, A., Neumann, G., Tilton, S. C., Schäfer, A., Li, C., et al. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0336-6 · Cited by 68
Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans
Mager, D. E., & Jusko, W. J. (2002) · Pharmaceutical Research · doi:10.1023/a:1020468902694 · Cited by 63
Cell-Cell Sensing of Viral Infection by Plasmacytoid Dendritic Cells
Webster, B., Assil, S., & Dreux, M. (2016) · Journal of Virology · doi:10.1128/jvi.01692-16 · Cited by 61
Immunotherapeutic effects of IL-7 during a chronic viral infection in mice
Nanjappa, S. G., Kim, E. H., & Suresh, M. (2011) · Blood · doi:10.1182/blood-2010-12-323154 · Cited by 59
Overly Exuberant Innate Immune Response to SARS-CoV-2 InfectionPreprint
Zhou, Z. L., Ren, X., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3551623 · Cited by 59
Ruscitti, P., Cipriani, P., Benedetto, P. D., Ciccia, F., Liakouli, V., Carubbi, F., Berardicurti, O., Rizzo, A. G., Triolo, G., & Giacomelli, R. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.004 · Cited by 54
Muskardin, T. W. (2020) · ACR Open Rheumatology · doi:10.1002/acr2.11140 · Cited by 48
The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis
Shamshirian, A., Hessami, A., Heydari, K., Alizadeh‐Navaei, R., Ebrahimzadeh, M. A., Yip, G. W. C., Ghasemian, R., Sedaghat, M., Baradaran, H., Yazdii, S. M., et al. (2020) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmed.sg.2020370 · Cited by 46
MAJEWSKA, E., Paleolog, E. M., Baj, Z., Kralisz, U., Feldmann, M., & Tchórzewski, H. (1997) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1997.d01-412.x · Cited by 36
Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review
Jamilloux, Y., Bélot, A., Magnotti, F., Benezech, S., Gerfaud‐Valentin, M., Bourdonnay, E., Walzer, T., Sève, P., & Henry, T. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8613-8 · Cited by 33
Self-citationFlammiger, A., Fiedler, W., Bacher, U., Bokemeyer, C., Schneider, M., & Binder, M. (2012) · Acta Haematologica · doi:10.1159/000338179 · Cited by 30
Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis.
Sterba, G., Sterba, Y., Stempel, C., Blank, J., Azor, E., & Gomez, L. B. (2010) · PubMed · Cited by 25
Cited by
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
“Mitigation of immunodysregulation is therefore viewed as amajor therapeutic avenue for the treatment andprevention of severe COVID-19 (Dimopoulos et al., 2020; Jamilloux et al., 2020).”
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
Zhang, J.-J., Dong, X., Liu, G.-H., & Gao, Y.-D. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 715
Zhu, Z., Lian, X., Su, X., Wu, W., Marraro, G. A., & Zeng, Y. (2020) · Respiratory Research · doi:10.1186/s12931-020-01479-w · Cited by 614
Pijls, B. G., Jolani, S., Atherley, A., Derckx, R. T., Dijkstra, J. I. R., Franssen, G. H. L., Hendriks, S., Richters, A., Venemans-Jellema, A., Zalpuri, S., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044640 · Cited by 586
Metadata
- Authors
- Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 19
- Issue
- 7
- Pages
- 102567
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W3021024241
- Cited by
- 658
- References
- 195
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.